<DOC>
	<DOCNO>NCT00364988</DOCNO>
	<brief_summary>Peroxisomal proliferator-activated receptor agonist pioglitazone rosiglitazone currently use treatment type 2 diabetes , efficient insulin sensitizer alone combination insulin.angiotensin II receptor antagonist losartan reduce level proteinuria.Whether Combination therapy pioglitazone losartan provide additional renoprotection subject type 2 diabetic nephropathy , 's worth researching .</brief_summary>
	<brief_title>Pioglitazone Losartan Provides Additional Renoprotection</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Fasting plasma glucose ( FPG ) level 3.39.0mmol/L 2h plasma glucose level 7.513 mmol/L serum creatinine value 190 660umol/L Two occasion ratio urinary albumin urinary creatinine≥300 24 hour urinary protein concentration ＞150mg Informed consent Type1 diabetes nondiabetic renal disease abnormal liver function heart dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>pioglitazone</keyword>
	<keyword>losartan</keyword>
	<keyword>proteinuria</keyword>
	<keyword>end stage renal disease ( ESRD )</keyword>
</DOC>